Halozyme Therapeutics announced that it will hold an Investor Conference Call on Wednesday, January 28, 2026, at 5:30 a.m. PT / 8:30 a.m. ET. Dr. Helen Torley, President and Chief Executive Officer, and Nicole LaBrosse, Chief Financial Officer, will lead the discussion. Pre-registration is available via the company’s website, and a live webcast will be accessible in the “Investors” section beginning 15 minutes before the call. A recording and presentation materials will be posted following the call’s conclusion.

On the call, Halozyme’s management team will provide preliminary unaudited full-year 2025 revenue results and updated financial guidance for 2026 through 2028. Investors can expect commentary on revenue drivers from key partnerships and product launches, as well as revised projections for top-line growth, operating expenses, and cash-burn estimates over the three-year outlook.

Halozyme’s proprietary ENHANZE® drug delivery technology, powered by the rHuPH20 enzyme, has enabled subcutaneous administration for ten commercialized products in more than 100 global markets, touching over one million patient lives. The company’s emerging Hypercon™ microparticle platform, designed to achieve ultra-high drug concentrations and reduced injection volumes, has been licensed to leading biopharmaceutical partners including Johnson & Johnson, Eli Lilly, and argenx.

In addition to its platform technologies, Halozyme commercializes two proprietary drug-device combination products—Hylenex® and XYOSTED®—and maintains active development collaborations with Teva Pharmaceuticals and McDermott Laboratories (Viatris affiliate). Headquartered in San Diego, CA, the company operates additional facilities in Ewing, NJ; Minnetonka, MN (operations site); and Boston, MA, supporting manufacturing, R&D, and corporate functions.